600518 康美药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.4930.1430.1211.465-31.860
总资产报酬率 ROA (%)0.2740.0760.0610.696-17.219
投入资产回报率 ROIC (%)0.4630.1350.1121.199-27.004

边际利润分析
销售毛利率 (%)21.30119.97514.78117.06715.143
营业利润率 (%)1.5460.667-0.4781.778-42.523
息税前利润/营业总收入 (%)1.7241.0080.7682.821-62.754
净利润/营业总收入 (%)1.6310.2370.2332.125-64.443

收益指标分析
经营活动净收益/利润总额(%)-125.290-251.877-915.188-18.66726.638
价值变动净收益/利润总额(%)199.120210.155170.78940.229-0.028
营业外收支净额/利润总额(%)13.63118.798171.53821.47433.277

偿债能力分析
流动比率 (X)1.3071.2631.1711.1161.357
速动比率 (X)0.8550.8380.7450.6830.851
资产负债率 (%)43.66144.58747.75450.41853.959
带息债务/全部投入资本 (%)-1.261-2.492-4.221-4.363-4.313
股东权益/带息债务 (%)-7,415.814-3,786.873-2,250.834-2,069.085-1,733.971
股东权益/负债合计 (%)128.396123.678108.88397.88484.895
利息保障倍数 (X)-26.2865.3827.6865.070-64.237

营运能力分析
应收账款周转天数 (天)176.371158.717151.277147.504143.032
存货周转天数 (天)226.677203.290209.796240.218301.709